Filing Details
- Accession Number:
- 0001209191-20-042500
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-15 17:00:16
- Reporting Period:
- 2020-07-14
- Accepted Time:
- 2020-07-15 17:00:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1661460 | Poseida Therapeutics Inc. | PSTX | Biological Products, (No Disgnostic Substances) (2836) | 472846548 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1685042 | Sean Murphy | C/O Poseida Therapeutics, Inc. 9390 Towne Centre Drive, Suite 200 San Diego CA 92121 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-07-14 | 7,013,918 | $0.00 | 7,013,918 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-07-14 | 1,168,985 | $0.00 | 8,182,903 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-07-14 | 690,124 | $0.00 | 8,873,027 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-07-14 | 315,098 | $0.00 | 9,188,125 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-07-14 | 10,000 | $16.00 | 10,000 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2020-07-14 | 8,746,356 | $0.00 | 7,013,918 | $0.00 |
| Common Stock | Series A-1 Preferred Stock | Disposition | 2020-07-14 | 1,457,725 | $0.00 | 1,168,985 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2020-07-14 | 860,585 | $0.00 | 690,124 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2020-07-14 | 392,927 | $0.00 | 315,098 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Billionaire Hedge Funds
